Research programme: immunomodulatory recombinant fusion proteins - Compugen

Drug Profile

Research programme: immunomodulatory recombinant fusion proteins - Compugen

Alternative Names: CGEN 15001 based protein therapeutics; CGEN 15001T based protein therapeutics; CGEN 15021 based protein therapeutics; CGEN 15022 based protein therapeutics; CGEN 15031 based protein therapeutics; CGEN 15051 based protein therapeutics; CGEN 15092 based protein therapeutics; CGEN-15029; CGEN-15029 based protein therapeutics; CGEN-15029/PVRIG; CGEN-15029/TIGIT; CGEN-15052 based protein therapeutics; CGEN-15091 based protein therapeutics; COM 701; COM701/PVRIG

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Compugen
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action CD28 antigen modulators; CD80 antigen modulators; Immunomodulators; Macrophage modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes mellitus

Most Recent Events

  • 02 Aug 2017 Compugen plans a phase I trial for Cancer
  • 26 Jul 2017 Bayer will return the rights to CGEN 15022 to Compugen
  • 25 Jul 2017 Compugen has patent protection for COM 701 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top